

# 1496 CANCER SUPPORT CLINIC USING KAMPO MEDICINE

Yoshiharu Motoo, MD, PhD, MACP

Department of Internal Medicine and Multidisciplinary Cancer Center, Fukui Saiseikai Hospital, Fukui 918-8503, JAPAN, e: motooy55@gmail.com



## Introduction

Patients with cancer experience coldness, sarcopenia, frailty, and decrease in biodefense during cancer chemotherapy. Kampo, a traditional Japanese medicine, has been applied to cancer supportive care using high-quality pharmaceutical products which are covered by universal national health insurance in Japan. Evidence is accumulating in terms of the efficacy and safety of Kampo, especially for refractory symptoms such as general malaise, anorexia, and peripheral neuropathy (PN). This report discusses the application of Kampo in a cancer support clinic in Japan.

## Patients

Patients with various kinds of cancer (solid tumors) were introduced to this clinic due to side effects of anti-cancer agents and so on. Most patients were actively treated with standard of care by organ-specific experts. Information on Kampo products can be obtained on the website of STORK (<http://mpdb.nibiohn.go.jp/stork/>).

## Results

From December 2021 to December 2023, a total of 23 patients were analyzed. The median age was 68 (range: 48–85) years and 13 (56.5%) were women. The most frequent symptom was chemotherapy-induced PN. Goshajinkigan (TJ-107) was used for paclitaxel-induced PN, and ninjin'yoeito (TJ-108) was used for oxaliplatin-induced PN. Other symptoms (and Kampo prescription) included niraparib-induced nausea & vomiting in a patient with recurrent ovarian cancer (heisan, TJ-79), multiple pain (not due to metastasis) in a postoperative patient with breast cancer (goshakusan, TJ-63), and oral mucositis in a patient with recurrent non-small cell lung cancer (hangeshashinto, TJ-14). In some patients, a single Kampo prescription effectively ameliorated multiple symptoms, indicating a potential polypharmacy solution.

## Conclusions

Kampo medicines, high-quality pharmaceutical products, have been well applied in cancer support clinic in Japan.




Fig. 1 The number of patients with each cancer site

How to take a package of Kampo extract easily: "water-oblate method"

We can take it just in one sip!

Photo by Yoshiharu Motoo


**STORK**  
(Standards of Reporting Kampo Products)

Motoo Y, Hakamatsuka T, Kawahara N, Arai I, Tsutani K. Standards of Reporting Kampo Products (STORK) in research articles. *J Integr Med.* 2017 May;15(3):182-185.

**Kampo for the Completion of Standard of Care**

Motoo Y. Roles of Kampo Medicine in Modern Cancer Therapy: Towards Completion of Standard Treatment. *Journal of Nippon Medical School* 2022 May; 89(2): 139-144.



Motoo Y, Cameron S. Kampo medicines for supportive care of patients with cancer: A brief review. *Integrative Medicine Research* 2022 Jun; 11(2):100839.



You will find 148 Kampo formulae which are covered by national health insurance in alphabetical order.

Table of the Links of Kampo Product informations in Japanese Pharmacopoeia (JP) and/or Package Insert

No.	Name in Roman Alphabet	Name in Han Character	Japanese Pharmacopoeia (JP)			Package insert (*)	Info (2)
			current version	JP XVII (2016)	JP XVII Suppl I (2017)		
1	anchusan	安中散				Q Ie Is	✓
2	bakumondoto	麦門冬湯	✓	✓		JO Ie Is	✓
3	bofutsushosan	防風通聖散	✓		✓	Q San Ie Is	✓
4	boiogito	防己黃耆湯	✓	✓	✓	JO Q Ie Is	✓
5	bukuryoin	茯苓飲				Is	✓
6	bukuryoingohangekobokuto	茯苓飲合半夏厚朴湯				Is	✓
7	bushirichuto	附子理中湯				San	✓
8	byakkokaninjinto	白虎加人參湯				Ie Is	✓
9	chikujountanto	竹茹溫胆湯				Is	✓
10	choijokito	調胃承氣湯				Is	✓
11	choreito	猪苓湯				Q San Ie Is	✓
12	choreitogoshimotsuto	猪苓湯合四物湯				Is	✓
13	chotosan	芍藥散	✓	✓		Is	✓
14	choyoto	懸壺湯				Is	✓
15	daibofuto	大防風湯				San Is	✓
16	daijokito	大承氣湯				Is	✓
17	daikenchuto	大建中湯	✓	✓		Is	✓
18	daiobotampito	大黃牡丹皮湯				Ie Is	✓
19	daiokanzoto	大黃甘草湯	✓	✓		Q Is	✓
20	daisaikoto	大柴胡湯	✓	✓		JO Q San Ie Is	✓



Motoo Y, et al. Prophylactic efficacy of ninjin'yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2). *Int J Clin Oncol.* 2020 Jun;25(6):1123-1129. PMID: 32232692